Lechenie erektil'noy disfunktsii: effekty‌‌ sildenafila

Cover Page

Cite item

Full Text

Abstract

Исследования в области нейрофизиологии эрекции привели к существенному прогрессу в лечении больных с эректильной дисфункцией ЭД. Они увенчались созданием принципиально нового средства в лечении данного заболевания - ингибитора фосфодиэстеразы 5-го типа (ФДЭ-5) силденафила, отвечающего всем современным требованиям, предъявляемым к терапии ЭД. Этот препарат признан средством 1-й линии в лечении ЭД, он высокоэффективен и надежен, прост в употреблении, обладает малым числом побочных эффектов. На сегодня силденафил является «золотым стандартом» в лечении ЭД.

About the authors

A. L Vertkin

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России

L. Yu Morgunov

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России

References

  1. Ayta I.A, Mc Kinlay J.B, Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84 (1): 50-6.
  2. Wagner G, Fugl-Meyer K.S, Fugl-Meyer A.R. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000; 4 (S1): 44-6.
  3. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418-32.
  4. Gresser U, Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435-46.
  5. Mc Cullough A.R. Four - year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26-38.
  6. Carson C.C. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488-96.
  7. Brown M, Prisant L.M, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70-3.
  8. Sunwoo S, Kim Y.S, Cho B.L et al. Post - marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res. 2005; 17 (1): 71-5.
  9. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7 (1): 47-56.
  10. Taylor J et al. Differences in side - effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009; 103: 1392-5.
  11. Leslie S.J et al. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76: 365-70.
  12. Kennedy S.H, Dugre H, Defoy I. A multicenter, double - blind, placebo - controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011; 26 (3): 151-8.
  13. Dording C.M, La Rocca R.A, Hails K.A et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013; 25 (1): 3-10.
  14. Abolyosr A, Elsagheer G.A, Abdel-Kader M.S et al. Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia - related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013; 5 (4): 237-40.
  15. Cui H, Liu B, Song Z et al. Efficacy and safety of long - term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2014 Jan 6; doi: 10.1111/and.12216.
  16. Spitzer M, Bhasin S, Travison T.G et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013; 1 (6): 913-8.
  17. Buvat J, Hatzichristou D, Maggi M et al. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102 (11): 1645-50.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies